Psychiatric Neuroscience: Incorporating Pathophysiology into Clinical Case Formulation

Massachusetts General Hospital Comprehensive Clinical Psychiatry

Volumn , Issue , 2008, Pages 543-564

  Morrow, Eric M ^a,b   Roffman, Joshua L ^a,b   Wolf, Daniel H ^c,d   Coyle, Joseph T ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898701606     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04743-2.50042-1     Document Type: Chapter

References (97)

1. DS Charney and EJ Nestler (2004) Neurobiology of mental illness ed 2 New York: Oxford University Press
2. KL Davis and American College of Neuropsychopharmacology (2002) Neuropsychopharmacology: the fifth generation of progress: an official publication of the American College of Neuropsychopharmacology Philadelphia: Lippincott Williams & Wilkins
3. ER Kandel, JH Schwartz and TM Jessell (1995) Essentials of neural science and behavior Norwalk, CT: Appleton & Lange
4. EJ Nestler, SE Hyman and RC Malenka (2001) Molecular neuropharmacology: a foundation for clinical neuroscience New York: McGraw-Hill
5. JR Cooper, FE Bloom and RH Roth (2003) The biochemical basis of neuropharmacology ed 8 New York: Oxford University Press
6. BH Price, RD Adams and JT Coyle (2000) Neurology and psychiatry: closing the great divide. Neurology 54(1), 8-14.
7. A Alzheimer, RA Stelzmann, HN Schnitzlein and FR Murtagh (1995) An English translation of Alzheimer's 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde,”. Clin Anat 8(6), 429-431.
8. A Alzheimer (1897) Beitrage zur pathologischen Anatomie der Dementia praecox. Monatsschr Psychiatr Neurol 2 82-120.
9. DA Lewis, T Hashimoto and DW Volk (2005) Cortical inhibitory neurons and schizophrenia. Nature Rev 6(4), 312-324.
10. FM Benes (2000) Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 31(2-3), 251-269.
11. MM Weber (1997) Aloys Alzheimer, a coworker of Emil Kraepelin. J Psychiatr Res 31(6), 635-643.
12. SS Kety (1988) Schizophrenic illness in the families of schizophrenic adoptees: findings from the Danish national sample. Schizophr Bull 14(2), 217-222.
13. SH Snyder (2006) Turning off neurotransmitters. Cell 125(1), 13-15.
14. I Creese, DR Burt and SH Snyder (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192(4238), 481-483.
15. P Seeman and T Lee (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188(4194), 1217-1219.
16. P De Camilli and TJ Carew (2000) Nobel celebrates the neurosciences. Modulatory signaling in the brain. Cell 103(6), 829-833.
17. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, fourth edition, text revision Washington, DC: American Psychiatric Association
18. F Plum (1972) Prospects for research on schizophrenia. 3. Neurophysiology. Neuropathological findings. Neurosci Res Program Bull 10(4), 384-388.
19. DD Dougherty, SL Rauch and JF Rosenbaum (2004) Essentials of neuroimaging for clinical practice Washington, DC: American Psychiatric Publishing
20. N Geschwind (1985) Mechanisms of change after brain lesions. Ann N Y Acad Sci 457 1-11.
21. J Fleischman (2002) Phineas Gage: a gruesome but true story about brain science Boston: Houghton Mifflin
22. S Corkin (2002) What's new with the amnesic patient H.M.? Nature Rev 3(2), 153-160.
23. RE Gur, ME Calkins, RC Gur, et al. (2007) The consortium on the genetics of schizophrenia: neurocognitive endophenotypes. Schizophr Bull 33(1), 49-68.
24. AR Hariri and DR Weinberger (2003) Imaging genomics. Br Med Bull 65 259-270.
25. MO Cunningham, J Hunt, S Middleton, et al. (2006) Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J Neurosci 26(10), 2767-2776.
26. RA deRegnier (2005) Neurophysiologic evaluation of early cognitive development in high-risk infants and toddlers. Ment Retard Dev Disabil Res Rev 11(4), 317-324.
27. S Kapur and D Mamo (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27(7), 1081-1090.
28. JT Coyle, G Tsai and D Goff (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003 318-327.
29. JJ Schildkraut (1967) The catecholamine hypothesis of affective disorders. A review of supporting evidence. Int J Psychiatry 4(3), 203-217.
30. J LeDoux (2003) The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 23(4-5), 727-738.
31. MF Bear, KM Huber and ST Warren (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27(7), 370-377.
32. WM Cowan, KL Kopnisky and SE Hyman (2002) The human genome project and its impact on psychiatry. Annu Rev Neurosci 25 1-50.
33. RE Tanzi and L Bertram (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120(4), 545-555.
34. RS Hill and CA Walsh (2005) Molecular insights into human brain evolution. Nature 437(7055), 64-67.
35. JP Amadio and CA Walsh (2006) Brain evolution and uniqueness in the human genome. Cell 126(6), 1033-1035.
36. K Mirnics, P Levitt and DA Lewis (2006) Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry 60(2), 163-176.
37. JA Gordon and R Hen (2004) Genetic approaches to the study of anxiety. Annu Rev Neurosci 27 193-222.
38. MJ Meaney and M Szyf (2005) Environmental programming of stress responses through DNA methylation: life at the interface between a dynamic environment and a fixed genome. Dialogues Clin Neurosci 7(2), 103-123.
39. JL Warner-Schmidt and RS Duman (2006) Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16(3), 239-249.
40. JL Rapoport, FX Castellanos, N Gogate, et al. (2001) Imaging normal and abnormal brain development: new perspectives for child psychiatry. Aust N Z J Psychiatry 35(3), 272-281.
41. SJ Webb, CS Monk and CA Nelson (2001) Mechanisms of postnatal neurobiological development: implications for human development. Dev Neuropsychol 19(2), 147-171.
42. RA Thompson and CA Nelson (2001) Developmental science and the media. Early brain development. Am Psychol 56(1), 5-15.
43. PR Huttenlocher, C De Courten, LJ Garey and H van der Loos (1982) Synaptic development in human cerebral cortex. Int J Neurol 16-17 144-154.
44. MJ Kreek, DA Nielsen, ER Butelman and KS LaForge (2005) Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nature Neurosci 8(11), 1450-1457.
45. SE Hyman, RC Malenka and EJ Nestler (2006) Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29 565-598.
46. GK Hulse, NT Lautenschlager, RJ Tait and OP Almeida (2005) Dementia associated with alcohol and other drug use. Int Psychogeriatr 17(suppl 1), S109-S127.
47. MM Mesulam (2000) Principles of behavioral and cognitive neurology ed 2 New York: Oxford University Press
48. S Heckers (2004) Functional neuroanatomy. TA Stern, JB Herman (Eds) The Massachusetts General Hospital psychiatry update and board preparation ed 2 New York: McGraw-Hill
49. JD Schmahmann (1991) An emerging concept. The cerebellar contribution to higher function. Arch Neurol 48(11), 1178-1187.
50. TJ Cullen, MA Walker, N Parkinson, et al. (2003) A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophr Res 60(2-3), 157-166.
51. S Heckers (1997) Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. Schizophr Bull 23(3), 403-421.
52. AM Graybiel (2005) The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol 15(6), 638-644.
53. CB Saper, G Cano and TE Scammell (2005) Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol 493(1), 92-98.
54. Y Ramon and S Cajal (1995) Histology of the nervous system of man and vertebrates New York: Oxford University Press
55. F Lopez-Munoz, J Boya and C Alamo (2006) Neuron theory, the cornerstone of neuroscience, on the centenary of the Nobel Prize award to Santiago Ramon y Cajal. Brain Res Bull 70(4-6), 391-405.
56. D Ongur, WC Drevets and JL Price (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 95(22), 13290-13295.
57. H Rauschka, B Colsch, N Baumann, et al. (2006) Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. Neurology 67(5), 859-863.
58. Y Hakak, JR Walker, C Li, et al. (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98(8), 4746-4751.
59. JA Girault and P Greengard (2004) The neurobiology of dopamine signaling. Arch Neurol 61(5), 641-644.
60. AF Arnsten, BP Ramos, SG Birnbaum and JR Taylor (2005) Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. Trends Mol Med 11(3), 121-128.
61. TD Gould, AM Picchini, H Einat and HK Manji (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Current Drug Targets 7(11), 1399-1409.
62. LM Luttrell (2006) Transmembrane signaling by G protein-coupled receptors. Methods Mol Biol 332 3-49.
63. JN Kew and JA Kemp (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179(1), 4-29.
64. JC Selcher, EJ Weeber, AW Varga, et al. (2002) Protein kinase signal transduction cascades in mammalian associative conditioning. Neuroscientist 8(2), 122-131.
65. TD Gould and HK Manji (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30(7), 1223-1237.
66. T Herdegen and JD Leah (1998) Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev 28(3), 370-490.
67. J Thome, N Sakai, K Shin, et al. (2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20(11), 4030-4036.
68. AV Turalba, KA Leite-Morris and GB Kaplan (2004) Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. Neurosci Lett 357(1), 53-57.
69. WA Carlezon Jr, RS Duman and EJ Nestler (2005) The many faces of CREB. Trends Neurosci 28(8), 436-445.
70. C Gaiddon, JP Loeffler and Y Larmet (1996) Brain-derived neurotrophic factor stimulates AP-1 and cyclic AMP-responsive element dependent transcriptional activity in central nervous system neurons. J Neurochem 66(6), 2279-2286.
71. R Blum and A Konnerth (2005) Neurotrophin-mediated rapid signaling in the central nervous system: mechanisms and functions. Physiology (Bethesda) 20 70-78.
72. M Neves-Pereira, JK Cheung, A Pasdar, et al. (2005) BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 10(2), 208-212.
73. M Neves-Pereira, E Mundo, P Muglia, et al. (2002) The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 71(3), 651-655.
74. J Schumacher, RA Jamra, T Becker, et al. (2005) Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 58(4), 307-314.
75. E Bossy-Wetzel, R Schwarzenbacher and SA Lipton (2004) Molecular pathways to neurodegeneration. Nature Med 10(suppl), S2-S9.
76. B Reisberg, R Doody, A Stoffler, et al. (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348(14), 1333-1341.
77. JK Rowlett, JM Cook, AN Duke and DM Platt (2005) Selective antagonism of GABAA receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs. CNS Spectrums 10(1), 40-48.
78. N Gervasi, Z Monnier, P Vincent, et al. (2003) Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures. J Neurosci 23(36), 11469-11478.
79. PS Goldman-Rakic (1998) The cortical dopamine system: role in memory and cognition. Adv Pharmacol 42 707-711.
80. VS Mattay, TE Goldberg, F Fera, et al. (2003) Catechol O-methyltransferase Val158Met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 100(10), 6186-6191.
81. EM Jolin, EB Weller and RA Weller (2006) Velocardiofacial syndrome: is there a neuropsychiatric phenotype? Curr Psychiatry Rep 8(2), 96-101.
82. EJ Nestler, M Alreja and GK Aghajanian (1999) Molecular control of locus coeruleus neurotransmission. Biol Psychiatry 46(9), 1131-1139.
83. V Arango, MD Underwood and JJ Mann (2002) Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 136 443-453.
84. HY Meltzer (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2 suppl), 106S-115S.
85. JP Hornung (2003) The human raphe nuclei and the serotonergic system. J Chem Neuroanat 26(4), 331-343.
86. CD Verrico, GM Miller and BK Madras (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189(4), 489-503.
87. AR Hariri, EM Drabant, KE Munoz, et al. (2005) A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62(2), 146-152.
88. L Pezawas, A Meyer-Lindenberg, EM Drabant, et al. (2005) 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nature Neurosci 8(6), 828-834.
89. J Bockaert, S Claeysen, C Becamel, et al. (2006) Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res 326(2), 553-572.
90. JL Cummings (2004) Alzheimer's disease. N Engl J Med 351(1), 56-67.
91. JM Witkin and DL Nelson (2004) Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 103(1), 1-20.
92. A Caspi and TE Moffitt (2006) Gene-environment interactions in psychiatry: joining forces with neuroscience. Nature Rev 7(7), 583-590.
93. A Caspi, K Sugden, TE Moffitt, et al. (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631), 386-389.
94. A Petronis, II Gottesman, TJ Crow, et al. (2000) Psychiatric epigenetics: a new focus for the new century. Mol Psychiatry 5(4), 342-346.
95. MJ Meaney and M Szyf (2005) Maternal care as a model for experience-dependent chromatin plasticity? Trends Neurosci 28(9), 456-463.
96. N Carey and NB La Thangue (2006) Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 6(4), 369-375.
97. M Gottlicher (2004) Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83(suppl 1), S91-S92.